Clinical Trials Logo
  1. Home
  2. Urea Cycle Disorder
  3. NCT03335488

Study of Glycerol Phenylbutyrate & Sodium Phenylbutyrate in Phenylbutyrate Naïve Patients With Urea Cycle Disorders (UCDs)

Urea Cycle Disorder Clinical Trial

Official title:
A Randomised, Controlled, Open-Label Parallel Arm Study of Safety, PK and Ammonia Control of RAVICTI® (Glycerol Phenylbutyrate) Oral Liquid and Sodium Phenylbutyrate in Phenylbutyrate Treatment Naïve Patients With Urea Cycle Disorders

Clinical Trial Summary

This is a randomized, controlled, open-label parallel arm study to assess the safety, tolerability, pharmacokinetics and ammonia control, of RAVICTI® as compared to Sodium phenylbutyrate (NaPBA) in urea cycle disorder subjects not currently or previously chronically treated with phenylacetic acid (phenylacetate; PAA) prodrugs. The study design will include: 1) Baseline Period; 2) Initial Treatment Period; 3) a RAVICTI only Transition Period 4) a RAVICTI only Maintenance Period; and 5) a RAVICTI only Safety Extension Period. The study will run for approximately 25 weeks.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03335488
Study type Interventional
Source Horizon Pharma Ireland, Ltd., Dublin Ireland
Contact
Status Completed
Phase Phase 4
Start date February 20, 2018
Completion date December 20, 2022
View Details
See also
  Status Clinical Trial Phase
Terminated NCT01948427 - Observational Study That Will Collect Information on Patients With Urea Cycle Disorders (UCDs)
Terminated NCT03933410 - UNLOCKED: A Phase 2, Open-label Trial With KB195 in Subjects With a Urea Cycle Disorder Phase 2
Completed NCT03064048 - Nitric Oxide Supplementation on Neurocognitive Functions in Patients With ASLD N/A
Recruiting NCT04612764 - Liver Disease in Urea Cycle Disorders
Completed NCT05330039 - Characterization of Intestinal Microbiota in Children With Inborn Errors of Metabolism (IEM)
Completed NCT03721367 - Chronic Liver Disease in Urea Cycle Disorders
Completed NCT03911089 - A Collection of Case Studies in Infants With UCD to Evaluate Infant Growth and the Safety of a New Medical Food for UCD N/A
Terminated NCT03181828 - Manipulating the Gut Microbiome Study Phase 1/Phase 2
Completed NCT00472732 - Neurologic Injuries in Adults With Urea Cycle Disorders N/A
Recruiting NCT05076318 - Dysregulated Urea-synthesis at Terminal Uremia N/A
Completed NCT03179878 - Safety and Tolerability of SYNB1020-CP-001 Phase 1
Recruiting NCT04602325 - Systemic Biomarkers of Brain Injury From Hyperammonemia
Withdrawn NCT03884959 - A Safety and Efficacy Study of Infusions of HepaStem in Urea Cycle Disorders Pediatric Patients Phase 2
Recruiting NCT04908319 - Hepatic Histopathology in Urea Cycle Disorders
Completed NCT02246218 - A Study of the Safety, Efficacy and Pharmacokinetics of Glycerol Phenylbutyrate in Pediatric Subjects Under 2 Years of Age With Urea Cycle Disorders Phase 4
Completed NCT04248062 - Patient and Observer Reported Outcome Measurements in Inborn Errors of Metabolism
Completed NCT05706714 - Th1, Th2, Th17 Phenotype in Urea Cycle Disorders
Terminated NCT03343756 - HepaStem Long-Term Safety Registry